Intellipharmaceutics International Inc. (IPCI)

[hogfan2]

from investor alley...may have already been posted..
2 Biotech Stocks under $10 to Scoop up Now
BRET JENSEN MARCH 15, 2015

IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) recently popped up on my radar due to a couple of positive analyst mentions. IntelliPharmaceutics is an emerging biopharmaceutical company based in Canada. The shares currently go for just under $2.50. Within the last month or so Brean Capital reiterated its “Buy” rating and $8.00 a share price target. Maxim Group did the same albeit with a $7.00 a share price target. Both of these came from highly ranked analysts within the biotech and biopharma space.

The company is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. The company’s proprietary Hypermatrix™ allows for the intelligent and efficient design of drugs through the precise control of a number of key variables.

The FDA recently approved the company’s generic version of the marketed drug Focalin XR® which has three-quarters of a billion dollars in annual sales. The drug will be distributed by IntelliPharmaCeutics partner Par Pharmaceutical Inc. The company has a half dozen other reformulated generic versions of drugs before the FDA through its Abbreviated New Drug Application filing process and the company is willing to take on a partner like Par Pharmaceutical for distribution.

In late summer, the company announced an enhancement to its Rexista abuse-deterrent technology. The new platform is called Podras (Paradoxical OverDose Reistance Activating Platform). The new platform potentially restricts the amount of active drug released in the body if more pills are consumed than prescribed while preserving the normal release of the drug if the amount consumed is as expected. Rexista technology prevents drug tampering while Podras addresses all forms of prescription drug misuse/abuse.

The most promising product being developed using this new technology combination is a generic oxycodone candidate. It’s an abuse-resistant version of this widely used drug with $2.3 billion in annual sales just in the United States. Given the company’s pipeline, myriad shots on goal, analyst support and minuscule $55 million market capitalization the stock is worth a small speculative position.

Although the small cap biotech and biopharma areas are inherently volatile spaces, I find both of these plays attractive from a risk/reward perspective at current levels.

Urgent: Back-Door Access to a $3.35 Billion Market Opportunity. Bret’s latest pick has found a legal method to circumvent the standard FDA approval process, meaning it’s products come to market faster and it’s R&D costs are significantly lower. It’s already up 156% since he first initiated coverage. NOW it’s set to grow as much as 2,715.13%! Click here to check out your next potential 10-bagger.




.http://www.investorsalley.com/2-biotech-stocks-under-10-to-scoop-up-now/